Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance

Study Purpose:

This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the EIM device can measure disease in muscle tissue.

Study Status:

Not recruiting

Disease:

Amyotrophic Lateral Sclerosis , Motor Neuron Disease , Charcot-Marie-Tooth Disease , Multiple Sclerosis

Study Type:

Observational

Type of Intervention:

N/A

Intervention Name:

N/A

Placebo:

N/A

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Jeremy Shefner, MD, PhD, State University of New York - Upstate Medical University

Clinicaltrials.gov ID:

NCT02011204

Neals Affiliated?

Yes

Coordinating Center Contact Information

Mass General Hospital

165 Cambridge Street
Boston, Massachusetts, 02114 United States

Full Study Summary:

This is a multicenter, 9-month study evaluating the effectiveness of electrical impedance myography (EIM) as a diagnostic and disease-tracking tool. In addition, the following will be studied:

1. Determine EIM device's ability to discriminate between ALS and "look-alike" non-fatal, motor-predominant syndromes;

2. Track EIM progression over time and determine the best summary EIM measure that could serve as an endpoint in future clinical trials and individual patient care; and,

3. Determine whether EIM progression is predictive of a combined outcome of survival and progression as measured by ALS Functional Rating Scale, Revised (ALSFRS-R), Hand-held Dynamometry (HHD) and Vital Capacity (VC) measures.

Study Sponsor:

Skulpt, Inc.

Participant Duration:

9 months

Estimated Enrollment:

106

Estimated Study Start Date:

10 / 31 / 2013

Estimated Study Completion Date:

03 / 01 / 2016

Posting Last Modified Date:

05 / 11 / 2016

Date Study Added to neals.org:

12 / 13 / 2013

For more information, please visit https://clinicalt...CT02011204&rank=1

Minimum Age:

35 Years

Maximum Age:

80 Years

Early ALS Inclusion Criteria:

- Sporadic or familial ALS (as defined by revised El Escorial criteria)

- Onset of weakness or spasticity due to ALS ≤ 36 months prior to the Screening/Baseline Visit.

- Slow vital capacity (SVC) ≥60% of predicted for gender, height, and age

Early ALS Exclusion Criteria:

- The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, or a history of active substance abuse within the prior year.

ALS Disease Mimics Inclusion Criteria:

- Diagnosis of one of the following:

a. Pure Lower Motor Neuron Disease (LMND) mimics: i. Multi-focal motor neuropathy ii. Autoimmune motor neuropathy iii. Cervical or lumbosacral radiculopathies with weakness involving more than one extremity or more than a single myotome if restricted to one extremity.

iv. Multiple peripheral mononeuropathies with clinical weakness v. Charcot-Marie-Tooth Disease vi. Any condition that produces generalized or localized weakness without concomitant sensory symptoms, including myasthenia gravis or myopathy, that the evaluating physician deems mimics ALS.

b. Pure Upper Motor Neuron Disease (UMND) mimics: i. Cervical myelopathy ii. Multiple sclerosis iii. Hereditary spastic paraparesis

ALS Disease Mimics Exclusion Criteria:

- Diagnosis of possible, probable, probable-laboratory supported, or definite ALS

- Presence of positive family history of ALS.

- The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, or a history of active substance abuse within the prior year.

Healthy Volunteer Inclusion Criteria:

- Absence of a known neurological disorder.

Healthy Volunteer Exclusion Criteria:

- History of ALS, myopathy, neuropathy, ALS mimic disorder or other neurodegenerative disease.

- Presence of positive family history of ALS.

- The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, or a history of active substance abuse within the prior year.

*Please note that this is not a complete listing on all eligibility criteria.*

St. Joseph's Hospital & Medical Center

Phoenix, Arizona 85013
United States

University of Miami Miller School of Medicine

Miami, Florida 33136
United States

Massachusetts General Hospital

Boston, Massachusetts 02114
United States

Skulpt, Inc

Boston, Massachusetts 02210
United States

SUNY Upstate Medical University

Syracuse, New York 13210
United States

Wake Forest University Health Sciences

Winston-Salem, North Carolina 27157
United States